Publish in OALib Journal
APC: Only $99
Objective: Long-acting darbepoetin-α (DA)
has recently been used to treat renal anemia in patients with chronic renal
failure. It is considered clinically useful because its duration of action is
longer than that of conventional epoetin-α.
In this study, we investigated changes in the levels of the oxidative stress
marker malondialdehyde-modified low density lipoprotein (MDA-LDL), renal
anemia, and renal function when patients were treated for chronic renal failure switched from epoetin-α to DA. Materials and Methods: The subjects included
nine patients with chronic renal failure and renal anemia who were treated with epoetin-α on an outpatient basis at our department. Blood was sampled prior to the
switch and at 3, 6, and 12 months after the switch. We then investigated
changes in MDA-LDL, hemoglobin (Hb), and creatinine (Cr) levels.